Savvy Updates, 5/9/22: FDA Stops Vertex Study, Extended Wear Infusion Set, Salaries at Dexcom

Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy study was reported by Annalee Armstrong for FierceBiotech.com, 2 May 2022.  

Vertex’s new diabetes cell therapy early study of VX-880 was placed on clinical hold after the FDA determined that there wasn’t enough evidence to support increasing the treatment dose as planned.  

Vertex reported data on the cell therapy from a single patient in October, which revealed that the patient achieved a “robust” restoration of islet cell function after receiving VX-880.

Leave a Reply

Your email address will not be published.